What body contouring procedures do GLP-1 weight loss patients need?

GLP-1 patients typically seek skin tightening, liposuction, and RF body-contouring treatments to address loose skin and localized fat deposits left after significant weight loss. These procedures target the sagging skin and stubborn pockets that diet and medication alone cannot resolve.

Is there a business opportunity for medspas in the GLP-1 weight loss trend?

Yes—GLP-1 responders represent a new, high-value patient cohort with defined procedural needs. Non-surgical options like RF microneedling and monopolar RF body treatments (InMode Forma, Cynosure platforms) are high-margin add-ons, though practices need surgical partnerships or dermatology relationships to capture this demand fully.

What RF body contouring devices work best for post-GLP-1 patients?

InMode Forma and Cynosure platforms are the leading monopolar RF body-contouring systems for this patient population. These non-invasive options provide skin tightening and fat reduction without surgery, making them ideal add-on treatments for medspas.

Why are standalone medspas losing GLP-1 patients to larger centers?

Standalone medspas without surgical capability or strong dermatology partnerships experience referral leakage because GLP-1 patients often need both surgical and non-surgical options. Larger practices and surgical centers can offer comprehensive treatment plans in-house, capturing the full patient lifetime value.

How much weight loss from GLP-1 drugs triggers body contouring demand?

The article references 'significant weight loss' as the trigger, though specific thresholds aren't detailed. Patients typically pursue contouring after achieving their target weight on Ozempic, Wegovy, or Mounjaro when loose skin becomes cosmetically bothersome.

Monday, August 24, 2026 Never miss a recall or a rule change Go Pro · $20/mo →

RegulatoryAbbVie Launches Phase 2 Forehead Lines Studytoday MarketFacial Rejuvenation Market Forecast to Hit $5.66B by 20302 days ago Business & M&AAllergan Aesthetics Overhauls Loyalty Programtoday Devices & TechXERF Technology Enters Australian Market for Skin Tightening2 days ago Business & M&AEvolus Expands Estyme to Canada, Australia, New Zealandtoday MarketArm Fat Now Top Body Sculpting Concern in Singapore2 days ago Devices & TechSofwave Hits One Million Treatments Milestonetoday RegulatoryCKD Bio Pursues China Botox Approval—2027 Launch Targeted2 days ago RegulatoryRevance Wins FDA Nod for Under-Eye Injectablesyesterday MarketGLP-1 Pill Era Is Forcing Beauty Market Shiftyesterday InjectablesAEON Releases Expanded ABP-450 Botox Biosimilar Datayesterday Devices & TechUltherapy PRIME Real-Time Imaging Reshapes Midface Liftingyesterday

Market

GLP-1 Weight Loss Boom Drives Post-Loss Body Contouring Demand at Aesthetic Practices

Ozempic and semaglutide uptake creates new patient flow for surgical and non-surgical body-sculpting procedures.

By Evan at Inside MedSpa · Jul 11, 2026

1-YEAR MOVE

INMD ▲1.0%

1-year price move by ticker
Ticker	Company	1-year change
INMD	InMode Ltd.	+1.0%

Blackhawk Plastic Surgery and other aesthetic practices report rising demand for post-weight-loss body contouring procedures, driven by the GLP-1 agonist boom (semaglutide, tirzepatide). Patients achieving significant weight loss via Ozempic, Wegovy, and Mounjaro are seeking surgical and non-surgical skin tightening, liposuction, and RF body-contouring treatments.

Inside MedSpa Pro

You've reached your free articles this week.

Keep reading every article, unlock the full trackers, and get the twice-a-week intelligence brief — from $20/mo, or $200/yr (two months free). Never miss a recall or a rule change.

Every article, unlocked — no weekly limit
The full 50-state law tracker, stock & M&A watch
The twice-a-week, 2-minute intelligence brief
Recalls, FDA clearances & safety signals as they hit

See everything you get →

Cancel anytime, one click · 14-day money-back on annual

https://insidemedspa.com/article/glp1-weight-loss-body-contouring-demand/

Discussion

Free alerts

Get flagged before it costs you.

We'll flag the moment a recall or rule change hits your practice. One email a week, one click to leave.

Free · weekly · unsubscribe anytime. Privacy.

This morning's brief · 6 AM

The free version stops here.

What today's moves mean for your margins — and exactly what to do — already went out to Pro. By the time the trade press explains it, the window to act has closed.

Go Pro · $20/mo Two minutes a morning. Cancel anytime.

Live · Market movers

STRATA Skin Sciences-50%Hims & Hers Health+6.03%Estée Lauder+6.02%Bausch Health (Solta)-5.43%The Beauty Health Company (HydraFacial)+3.65%

The full stock & M&A watch →

FDA Activity — Aesthetic Devices

Monthly 510(k) clearances vs. recalls.

510(k) clearances Recalls

FDA Activity — Aesthetic Devices — Monthly 510(k) clearances vs. recalls.
Month	510(k) clearances	Recalls
Jun '25	0	4
Jul '25	0	1
Sep '25	0	1
Oct '25	0	2
Jan '26	0	1
Feb '26	0	5
Mar '26	0	5
Apr '26	0	19
May '26	7	18
Jun '26	34	8
Jul '26	23	4
Aug '26	5	0

The 50-state regulation tracker →

Inside MedSpa Pro

By the time it's news, it's too late.

The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

Go Pro · $20/mo Never miss a recall or a rule change. Cancel anytime.

The twice-a-week intelligence brief Go Pro · $20/mo →

GLP-1 Weight Loss Boom Drives Post-Loss Body Contouring Demand at Aesthetic Practices

Share

Discussion

Leave a comment

By the time it's news, it's too late.